Welcure Drugs & Pharmaceuticals Ltd announced its financial results for the quarter ending June 30, 2025 (Q1FY26).
Welcure Drugs & Pharmaceuticals has reported a substantial financial performance in Q1FY26, with revenue from operations increasing sharply to ₹299.91 crore. This is a significant improvement from ₹21.21 crore in the previous quarter (Q4FY25), reflecting a remarkable 1300% rise on a quarter-on-quarter (Q-o-Q) basis. Such an impressive surge highlights the company’s successful business strategies and its growing foothold in export-oriented services.
In terms of profitability, Welcure has reported a net profit of ₹23.29 crore for Q1FY26, a remarkable turnaround from a net loss of ₹0.34 crore during the same period in the previous year (Q1FY25). The company has also seen an 830% rise in its net profit when compared to Q4FY25, which posted a net profit of ₹2.5 crore.
One of the significant contributors to Welcure's stellar performance is its shift towards export sourcing services. The company successfully completed seven export-sourcing assignments, with a total value of ₹299.91 crore. In these transactions, Welcure acted solely as a procurement agent on behalf of international buyers, earning a fixed 5% commission on each deal. This model allows the company to generate revenue without exposing itself to risks related to inventory, logistics, or working capital, ensuring its debt-free structure remains intact.
Further enhancing its growth prospects, Welcure secured a major global sourcing mandate worth ₹517 crore from Thailand-based Fortune Sagar Impex Company Limited. This deal is expected to contribute approximately ₹25.85 crore in service income during FY26.
Read More: Anant Raj Share Price in Focus: Expands Data Centre Business, Targeting ₹1,200 Crore by FY27!
To strengthen its leadership and governance, Welcure has made strategic appointments to its board. Mr Rabi Thakor has been appointed as an Additional Non-Executive Non-Independent Director, while Mr Yogeshkumar Prajapati and Mrs Bhumika Pradhan have been appointed as Additional Independent Directors. These leadership changes are aimed at driving the company’s strategic initiatives and ensuring sustainable growth in the coming years.
On the back of these impressive financial results and strategic developments, Welcure’s share price hit the upper circuit limit of 5% on August 5, 2025.
Welcure Drugs & Pharmaceuticals Ltd has set a solid foundation for growth in FY26 with strong financial results in Q1, driven by strategic moves into export sourcing services.
Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in securities are subject to market risks. Read all related documents carefully before investing.
Published on: Aug 5, 2025, 3:54 PM IST
Team Angel One
We're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
